美国胃肠病学会年会溃疡性结肠炎亮点：评论 - Suppr

Highlights in Ulcerative Colitis From the ACG Annual Scientific Meeting: Commentary.

作者信息

Rubin David T

机构信息

Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center The University of Chicago Medicine, Chicago, Illinois.

出版信息

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):13-16.

PMID:36866201

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9972644/

Abstract

摘要

相似文献

Highlights in Ulcerative Colitis From the ACG Annual Scientific Meeting: Commentary.美国胃肠病学会年会溃疡性结肠炎亮点：评论

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):13-16.

Report from the ACG. Highlights from the American College of Gastroenterology. 66th Annual Scientific Meeting. October 19-23, 2001, Las Vegas, NV.美国胃肠病学会报告。美国胃肠病学会亮点。第66届年度科学会议。2001年10月19日至23日，内华达州拉斯维加斯。

Rev Gastroenterol Disord. 2001;1(4):199-205.

Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会2023年年度科学会议溃疡性结肠炎亮点：评论

Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):13-18.

Highlights in Primary Biliary Cholangitis From the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, and the AASLD 2020 Liver Meeting Digital Experience: Commentary.来自欧洲肝脏研究学会（EASL）2020年数字国际肝脏大会、美国胃肠病学会（ACG）2020年虚拟年度科学会议以及美国肝病研究学会（AASLD）2020年肝脏会议数字体验的原发性胆汁性胆管炎亮点：评论。

Gastroenterol Hepatol (N Y). 2021 Feb;17(2 Suppl 3):13-15.

Highlights in Crohn's Disease From the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会（ACG）2023年年度科学会议克罗恩病亮点：评论

Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 8):23-27.

Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 ACG Meeting.克罗恩病与溃疡性结肠炎的当前研究：2010年美国胃肠病学会会议亮点

Gastroenterol Hepatol (N Y). 2010 Dec;6(12):3-14.

A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版：欧洲克罗恩病和结肠炎组织（ECCO）第14届大会炎症性肠病亮点：对第14届欧洲克罗恩病和结肠炎组织（ECCO）大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY：维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析：维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合：U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性：GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗（PAILOT）随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗：中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性：EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究：疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析医学教授胃肠病学和肝病科梅奥诊所明尼苏达州罗切斯特

Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.

Best of ACG 2006: Highlights From the 71st Annual Scientific Meeting of the American College of Gastroenterology, October 20-25, 2006, Las Vegas, Nevada.2006年美国胃肠病学会最佳成果：2006年10月20日至25日在内华达州拉斯维加斯举行的第71届美国胃肠病学会年度科学会议亮点

Gastroenterol Hepatol (N Y). 2007 Jan;3(1):41-8.

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.系统评价和荟萃分析：英夫利昔单抗和阿达木单抗治疗溃疡性结肠炎的应答丧失和需要剂量递增。

Inflamm Bowel Dis. 2023 Oct 3;29(10):1633-1647. doi: 10.1093/ibd/izac200.

Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.欧洲克罗恩病和结肠炎组织第17届大会溃疡性结肠炎亮点：评论

Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):13-16.

本文引用的文献

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.VEDOLIZUMAB 和 USTEKINUMAB 暴露妊娠的母婴结局：PIANO 注册研究结果。

Am J Gastroenterol. 2024 Mar 1;119(3):468-476. doi: 10.14309/ajg.0000000000002553. Epub 2023 Oct 5.

Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.中重度活动性溃疡性结肠炎诱导和维持期先进疗法的疗效与安全性：一项使用贝叶斯网络荟萃分析的间接治疗比较

Crohns Colitis 360. 2023 Mar 1;5(2):otad009. doi: 10.1093/crocol/otad009. eCollection 2023 Apr.

Induction Combination Therapy With Guselkumab and Golimumab Followed by Guselkumab Monotherapy Maintenance: Results of the Phase 2a, Randomized, Double-Blind, Proof-of-Concept VEGA Study.古塞库单抗与戈利木单抗诱导联合治疗后采用古塞库单抗单药维持治疗：2a期随机双盲概念验证性VEGA研究结果

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):10-11.

The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy.古塞库单抗诱导疗法对中度至重度活动性溃疡性结肠炎患者的疗效：QUASAR 2b期诱导治疗第12周时既往对先进疗法反应不足或不耐受患者的结果

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):12-13.

Duration of Response to Ozanimod After Treatment Withdrawal: Results From the Phase 3 True North Study.撤药后对奥扎莫德的反应持续时间：3期真实北方研究的结果

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):2-3.

Benefits of High Versus Low Dose Upadacitinib as Maintenance Treatment in Ulcerative Colitis Patients Who Were Responders to 8-week Induction With Upadacitinib: Results From the U-ACHIEVE Phase 3 Maintenance Trial.在对乌帕替尼进行8周诱导治疗有反应的溃疡性结肠炎患者中，高剂量与低剂量乌帕替尼作为维持治疗的益处：U-ACHIEVE 3期维持试验的结果

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):4-5.

One-Year Comparative Effectiveness of Ustekinumab Versus Tofacitinib for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure.优特克单抗与托法替布在抗肿瘤坏死因子治疗失败后用于溃疡性结肠炎的一年期对比疗效

Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):7-8.

Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North.对于未使用过免疫调节剂和生物制剂、5-氨基水杨酸治疗失败的溃疡性结肠炎患者，奥扎莫德是一种有效的口服疗法：来自真实北方研究的事后分析

Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):4-5.

Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.维得利珠单抗与抗肿瘤坏死因子药物相比，在老年人中发生严重感染的风险较低。

Clin Gastroenterol Hepatol. 2022 Jun;20(6):1299-1305.e5. doi: 10.1016/j.cgh.2021.08.047. Epub 2021 Sep 3.

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.奥扎莫德（RPC1063）是一种强效的1-磷酸鞘氨醇受体-1（S1P1）和受体-5（S1P5）激动剂，具有改善自身免疫性疾病的活性。

Br J Pharmacol. 2016 Jun;173(11):1778-92. doi: 10.1111/bph.13476. Epub 2016 Apr 28.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验